Pravostranné selhání po implantaci levostranné mechanické srdeční podpory - editorial

J. Bělohlávek

Vnitr Lek 2010, 56(1):5-7  

Paraneoplastický tromboembolický syndrom jako první příznak zhoubného onemocnění - editorial

D. Karetová

Vnitr Lek 2010, 56(1):8-10  

Cancer and deep vein thrombosis - editorial

J. Malý

Vnitr Lek 2010, 56(1):11-13  

Cancer patients with thrombosis and haemorrhagy are a particular problem. They have an increased risk of deep vein thrombosis and pulmonary embolism, and they're more prone to bleeding from anticoagulant therapy. So it really is a dilemma. Clinical research has shown that prevention and initial therapy can consist of subcutaneous low-molecular-weight heparin for an initial period, followed by long-term anticoagulant therapy.

The influence of 6-months treatment with exenatide on type 2 diabetes mellitus compensation, anthropometric and biochemical parameters

T. Roubíček, M. Mráz, M. Bártlová, P. Kaválková, D. Haluzíková, P. Trachta, J. Housová, M. Matoulek, Š. Svačina, M. Haluzík

Vnitr Lek 2010, 56(1):15-20  

Objectives:Exenatide, a synthetic GLP-1 analogue, is a new antidiabetic agent from the group of incretine mimetics coming into the daily clinical practice. In our study we evaluated the effect of 6-months treatment with exenatide on diabetes compensation, anthropometric and biochemical parameters in the patients with poorly controlled type 2 diabetes mellitus and obesity. Method:We included 18 patients with poorly controlled diabetes (mean HbA_1c 8.5 ± 0.3%) treated with diet and peroral antidiabetic agents (4 patients were treated with insulin in the past). Exenatide was administered via subcutaneous injection...

Pilot register of acute myocardial infarction - a 5-year evaluation of quality of care in non-PCI hospitals

Z. Monhart, H. Grünfeldová, P. Janský, J. Zvárová, V. Faltus

Vnitr Lek 2010, 56(1):21-29  

Introduction:The aim of this research was to describe (demographic data and cardiovascular disease risk factors) a non-selected patient population with acute myocardial infarction and to evaluate the applied diagnostic and therapeutic approaches. Patients and methods:Data on 3,184 cases of acute myocardial infarction from non-PCI hospitals in Čáslav, Chrudim, Jindřichův Hradec, Kutná Hora, Písek and Znojmo were entered in a pilot register between 2003 and 2007. Results:ST elevation myocardial infarctions represented 28.5% of registered cases; primary reperfusion was indicated in 68.3% of these cases. Coronarography...

Right ventricular dysfunction after left ventricular assist device implantation

H. Říha, I. Netuka, T. Kotulák, J. Malý, M. Pinďák, P. Kellovský, F. Kopáč, D. Hodr, O. Szárszoi, J. Kettner, H. Al-Hiti, Z. Dorazilová, T. Marek, I. Skalský, J. Pirk

Vnitr Lek 2010, 56(1):30-36  

Objective:The frequency of long-term left ventricular assist device (LVAD) implantation is increasing. Acute right ventricular dysfunction or right ventricular failure after LVAD implantation has important influence on morbidity and mortality. The aim of our study was to assess the management of right ventricular dysfunction after LVAD implantation. Methods:The study group comprised 21 patients with implanted HeartMate II® LVAD since December, 2006 to April, 2009. We evaluated in retrospective fashion baseline parameters of cardiovascular and other organ systems before LVAD implantation, applied pharmacological and mechanical...

Patients older than 80 years with de novo acute myeloid leukemias without erythroblastic and/or megakaryocytic dysplasia achieve complete remission and longer survival after classical chemotherapy 3 + 7

P. Lemež, J. Gáliková, K. Michalová, D. Dvořáková, A. MacWhannell, Z. Zemanová, J. Stejskal

Vnitr Lek 2010, 56(1):37-43  

Chemotherapy in most patients with AML over 80 years of age is not recommended because their median survival is about 1 month. The aim of our study was to identify patients in this age group who might achieve complete remission with standard dose chemotherapy. We report 9 consecutive patients with de novo AML diagnosed and treated in 1992-2008. All bone marrow samples were hypercellular, classified as FAB types M2 in 2 cases, M4 in 6, and M5 in one case. Three patients opted for supportive or palliative therapy and survived 1-4 months. Six patients received standard dose chemotherapy. Two patients with a normal karyotype had resistant AML and survived...

Clinical perspective of precancerotic states in gastroenterology and their molecular genetics

P. Mináriková, M. Zavoral

Vnitr Lek 2010, 56(1):44-48  

Gastrointestinal tract tumours represent an important cause of death in the Czech Republic. Diagnosis of the disease at its advanced stage with progression precluding radical surgical solution is a frequent common denominator. Detection of precancerous states, including congenital genetic defects or premalignant syndromes and malignant lesions may serve as a useful tool for early detection of disease risk or disease onset. Considering the incidence of individual types of tumours, this paper focuses mainly on precancerotic states leading to malignant alterations of oesophagus, colorectum and pancreas. Apart from a concise morphological description of...

Paraneoplastic thromboembolic syndrome as the first sign of a malignant disease

M. Žuffa

Vnitr Lek 2010, 56(1):49-52  

We describe the paraneoplastic thromboembolic syndrome in venous and arterial (coronary, cerebral, peripheral) systems and in the heart (paraneoplastic endocarditis). We emphasise that the syndrome may signal presence of an occult malignant disease that, at that time, might be treatable.

Epidemiology of vascular disease

T. Pišková, P. Gavorník

Vnitr Lek 2010, 56(1):53-58  

In the European Union are vascular diseases the main cause of death, causing 1.9 millions of deaths per year. The highest mortality rates for cardiovascular diseases are found in Slovakia (data provided by National center health information, 2006). In 2007 died 29,289 (54.1%) persons from cardiovascular diseases, which means more than half of all deaths. From all men 47.8% died from cardiovascular diseases and from all women died 61.6% for cardiovascular disease. Coronary heart disease (55%) presents more than half causes of these deaths. Despite that mortality from cardiovascular disease has been continuously decreasing, in Central and East European...

Surgical interventions in patients with myeloproliferative disease - prophylaxis and treatment of haemostatic disorders

P. Dulíček, J. Voglová, J. Malý

Vnitr Lek 2010, 56(1):61-66  

Despite many decades of laboratory and clinical research of pathogenesis bleeding and thrombosis and the search for the identification of the risk factors, the accomplished results are unsatisfactory in clinical praxis. In our article, we discuss incidence, pathogenesis, clinical manifestation and the risk factors for coagulopathy in patients with myeloproliferative disease. The surgical procedures are associated with higher risk of morbidity and mortality. The aim of the article is the formulation of the recommendations concerning management of surgical interventions with the goal to reduce the risk of bleeding and thrombotic diathesis.

A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review

Z. Adam, M. Matýšková, M. Krejčí, L. Pour, J. Kissová, M. Šlechtová, G. Chlupová, Y. Stavařová, J. Simonides, M. Penka, J. Mayer, R. Hájek

Vnitr Lek 2010, 56(1):67-78  

Disturbance of haemostasis and bleeding are rather frequent complications of AL amyloidosis. These are frequently caused by increased fragility of capillaries, thrombocyte function disorders and coagulation cascade defects. The most frequent coagulation disorder is decreased factor X activity. We describe a 34-year old female after hysterectomy for myomatous uterus and metrorhagia. Before the surgery, the attending physicians did not identify any pathological changes suggesting a need for further investigations or presence of AL amyloidosis. Post-surgery development was complicated by life-threatening diffuse haemorrhage. Extended investigations of...

Cardiac tumor in a pregnant patient

M. Třetina, M. Hrdlička, J. Ondrášek, P. Němec, M. Orban

Vnitr Lek 2010, 56(1):79-81  

Cardiac myxoma represents the most frequent cardiac tumor with a relatively low overall incidence. Clinical symptoms are hetereogeneous and therefore nonspecific. With regard to high success of the surgical treatment, early diagnosis is crucial. We present a case of cardiac myxoma in a pregnant woman, which was succesfully sugically removed.

Ferenčík M et al. Zápal - fundamentálny princíp vzniku chorôb

Jindřich Lokaj

Vnitr Lek 2010, 56(1):87  

Profesor MUDr. Jozef Zimáček, CSc., zomrel. *26. januára 1933 †19. mája 2009

M. Mydlík, K. Derzsiová

Vnitr Lek 2010, 56(1):82-83  

Prof. MUDr. Pavol Schweitzer, CSc., významný reprezentant internistickej školy prof. MUDr. Františka Póra - osemdesiatročný

M. Mydlík, K. Derzsiová

Vnitr Lek 2010, 56(1):84-86